Article

Two bottle limit defines optimal medical therapy

San Francisco - Optimal medical therapy for most patients needing IOP-lowering treatment may be as simple as one or two bottles, said Robert D. Fechtner, MD, professor of ophthalmology, director, glaucoma division, Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.

San Francisco - Optimal medical therapy for most patients needing IOP-lowering treatment may be as simple as one or two bottles, said Robert D. Fechtner, MD, professor of ophthalmology, director, glaucoma division, Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.

“Addition of a third bottle rarely provides substantial additional reduction in IOP, so I would recommend changing the second drug before going to a third, and if that fails, consider laser or incisional surgery next,” he commented.

Ophthalmologists who prescribe medications for glaucoma need to realize that it is the patient who is really treating the disease, not the physician, and so the reality is that there may be no relationship between what is prescribed and what is used.

With that in mind, the optimal medication regimen should be simple, practical, affordable, effective, and well tolerated. Treatment that includes three different bottles of medication is unlikely to fulfill many of those criteria.

Dr. Fechtner recommended starting with a prostaglandin analogue and adding a second drug if further IOP-lowering is needed. However, he noted there are more than 56,000 possible combinations of topical glaucoma drugs and there have been few well-designed studies comparing the additivity of a second agent with a prostaglandin.

Beta-blockers are a popular choice, although other classes should not be overlooked, and in his practice, Dr. Fechtner indicated he often uses the fixed combination timolol/dorzolamide (Cosopt, Merck) for a second bottle.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.